{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-013802","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2024-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.691469+00:00","generated_at":"2026-05-30T09:21:57.289567+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Harmony Biosciences Q3 net revenue $186M (+16% YoY); reiterates FY2024 guidance $700-720M","bullets":["GAAP net income $46.1M ($0.79 diluted EPS) vs $38.5M ($0.63) in Q3 2023; non-GAAP adjusted EPS $1.03.","Average WAKIX patients ~6,800 (+250 sequentially); cumulative net revenue surpasses $2B since 2019 launch.","On track to submit sNDA for pitolisant in idiopathic hypersomnia in Q4 2024; LTS data show sustained efficacy.","Pipeline: EPX-100 Phase 3 for Dravet syndrome (data 2026); Phase 3 for LGS to start by year-end; ZYN-002 topline mid-2025.","Reiterates FY2024 net product revenue guidance of $700-$720 million."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-013802","json":"https://secwatch.observer/filing/0001558370-24-013802.json","markdown":"https://secwatch.observer/filing/0001558370-24-013802.md","text":"https://secwatch.observer/filing/0001558370-24-013802.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837024013802/0001558370-24-013802-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837024013802/hrmy-20241029x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:21:57.289567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}